Fundraising Fox

AntriaBio

NASDAQ: RZLT

Louisville, US · Founded 2010 · Nevada corporation · 1 known investors

Biotech

Founders & leadership

SM
Sankaram MantripragadaExecutive
NC
Nevan Charles ElamExecutive
ML
Morgan Lynn FieldsExecutive

Board

HH
Hoyoung HuhBoard director
BS
Barry ShermanBoard director
SR
Steve R. HoweBoard director

Investors · 1

Bay City CapitalSan Rafael · $5M – $10M

Reported raises · per SEC filings

Form D private placements

$85M disclosed across 11 rounds · 2013–2020

▶$41MraisedOct 2020 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith VendolaExecutive Officer
  • Young-Jin KimDirector
  • Jung-Hee LimDirector
  • Philippe FauchetDirector
  • Sankaram MantripragadaExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Gil LabrucherieDirector
Offering amount
$57M
Amount sold
$41M
Sales commissions
$2.5M
Placement agents
Griffin Securities, Inc., JMP Securities LLC, Canaccord Genuity LLC
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedApr 2018 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David F. WelchDirector
  • Hoyoung HuhExecutive Officer, Director
  • Gil LabrucherieDirector
  • Sankaram MantripragadaExecutive Officer
  • Morgan Lynn FieldsExecutive Officer
  • Tae Hoon KimDirector
  • Brian RobertsExecutive Officer
  • Noopur Batsha LiffickExecutive Officer
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Nevan Charles ElamExecutive Officer, Director
Offering amount
$6M
Amount sold
$4.8M
Sales commissions
$202.3K
Placement agents
Brookline Capital Markets, a division of CIM Securities, LLC
First sale
Jan 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedFeb 2018 · 190 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tae Hoon KimDirector
  • Gil LabrucherieDirector
  • Nevan Charles ElamExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
  • Hoyoung HuhExecutive Officer, Director
  • David F. WelchDirector
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Noopur Batsha LiffickExecutive Officer
  • Sankaram MantripragadaExecutive Officer
  • Brian RobertsExecutive Officer
Offering amount
$25.4M
Amount sold
$3.4M
First sale
Jan 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$137.9KraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tae Hoon KimDirector
  • Sankaram MantripragadaExecutive Officer
  • David F. WelchDirector
  • Brian RobertsExecutive Officer
  • Michael R. DeperroExecutive Officer
  • Noopur Batsha LiffickExecutive Officer
  • Samir R. PatelDirector
  • Hoyoung HuhExecutive Officer, Director
  • Gil LabrucherieDirector
  • Nevan Charles ElamExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
Offering amount
$10.1M
Amount sold
$137.9K
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedMay 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nevan Charles ElamExecutive Officer, Director
  • Tae Hoon KimDirector
  • Brian RobertsExecutive Officer
  • Sankaram MantripragadaExecutive Officer
  • David F. WelchDirector
  • Morgan Lynn FieldsExecutive Officer
  • Barry ShermanDirector
  • Michael R. DeperroExecutive Officer
  • Samir R. PatelDirector
  • Noopur Batsha LiffickExecutive Officer
  • Hoyoung HuhExecutive Officer, Director
Offering amount
$15M
Amount sold
$6.7M
First sale
Mar 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.4MraisedJul 2016 · 60 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hoyoung HuhExecutive Officer, Director
  • Morgan Lynn FieldsExecutive Officer
  • David WelchDirector
  • Sankaram MantripragadaExecutive Officer
  • Barry ShermanDirector
  • Nevan Charles ElamExecutive Officer, Director
Offering amount
$53.3M
Amount sold
$5.4M
Sales commissions
$2M
Placement agents
CIM Securities, LLC, Paulson Investment Company, Inc.
First sale
Jun 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedMar 2016 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry ShermanDirector
  • Morgan Lynn FieldsExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Hoyoung HuhExecutive Officer, Director
  • Sankaram MantripragadaExecutive Officer
  • David WelchDirector
Offering amount
$16.7M
Amount sold
$4.3M
Sales commissions
$737.5K
Placement agents
CIM Securities, LLC, Brookline Group, LLC
First sale
Dec 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedApr 2015 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry ShermanDirector
  • Hoyoung HuhDirector, Executive Officer
  • Morgan Lynn FieldsExecutive Officer
  • Nevan Charles ElamExecutive Officer, Director
  • Sankaram MantripragadaExecutive Officer
Offering amount
$4.7M
Amount sold
$2M
Sales commissions
$98.4K
Placement agents
Paulson Investment Company, Inc.
First sale
Mar 2015
Incorporated
Corporation, Delaware, 2010
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

AntriaBio raises $13m for injectable, once-weekly insulin - Drug Delivery Businessdrugdeliverybusiness.com · Jul 2017AntriaBio, Inc. announced that it expects to receive $15 million in funding | MarketScreenermarketscreener.com · Mar 2017AntriaBio snaps up $12M in private placement deal | Fierce Pharmafiercepharma.com · Jul 2016AntriaBio Announces $12 Million Private Placementfinance.yahoo.com · Jun 2016AntriaBio raises $7 million to work on insulin – BizWestbizwest.com · Jan 2015

Frequently asked questions

Who are AntriaBio's investors?
AntriaBio's investors include Bay City Capital.
How much funding has AntriaBio raised?
AntriaBio has disclosed $85M raised across 11 rounds.
Where is AntriaBio headquartered?
AntriaBio is headquartered in Louisville, US.